Parkinson's Disease最新文献

{"title":"Genome-Wide Association Studies Data and Transcriptomics Data Link Herpes Simplex Virus 1 Infection and Parkinson's Disease.","authors":"Changhao Lu, Xinyi Cai, Elena Simula, Tommaso Ercoli, Paolo Solla, Leonardo A Sechi","doi":"10.1155/padi/4044371","DOIUrl":"10.1155/padi/4044371","url":null,"abstract":"<p><strong>Objective: </strong>The main goal of this study is to explore the link between herpes simplex virus 1 (HSV-1) infection and Parkinson's disease (PD) from the genome-wide association studies (GWAS) data and find the shared molecular signature for mechanism understanding and drug repurposing from the transcriptomics data.</p><p><strong>Methods: </strong>We used summary-level GWAS data for causal inference, exploring the association between herpes keratitis (mainly caused by HSV-1) and PD, and used transcriptomics data to study the shared molecular signature for mechanism understanding and drug repurposing.</p><p><strong>Results: </strong>The causal inference analysis implied that HSV-1 infection is related to PD. The upregulated shared gene set between HSV-1 infection and PD is mainly enriched in neuroinflammation, while the downregulated shared gene set is mainly enriched in stem cell and cellular metabolism, and the drug repurposing targeted the shared molecular signature nalfurafine.</p><p><strong>Conclusion: </strong>HSV-1 infection is related to PD, and these two diseases had shared molecular signature such as neuroinflammation and stem cell, which could be targeted for drug repurposing.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"4044371"},"PeriodicalIF":2.2,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clove Essential Oil Enhances Antioxidant Defenses and Reduces DNA Damage in a Cellular Model of Parkinson's Disease.","authors":"Dhouha Hamdi, Omar Ouachik, Ayhan Kocer, Lemlih Ouchchane, Chokri Messaoud, Aziz Hafidi","doi":"10.1155/padi/4243787","DOIUrl":"10.1155/padi/4243787","url":null,"abstract":"<p><p>Oxidative stress is a major contributor to the pathogenesis of Parkinson's disease, promoting neuronal degeneration through the production of excessive reactive oxygen species. In this context, natural products such as essential oils are attracting increasing attention for their potential to protect neurons. Clove essential oil (CEO), which is extracted from the flower buds of the plant Syzygium aromaticum, is renowned for its antioxidant activity. This study aimed to investigate the chemical composition, antioxidant properties, and protective effects of CEO on SH-SY5Y cells, which are used as a cellular model of Parkinson's disease. The CEO was obtained by hydrodistillation (yield: 15%) and is primarily composed of eugenol (84.49%) and acetyl-eugenol (10.05%). Its antioxidant activity was confirmed via DPPH radical scavenging (IC₅₀ = 0.081 ± 0.001 mg/mL) and iron chelation (110.32 ± 0.67 mg EDTA equivalent/g essential oil (EO)). qRT-PCR, Western blot, and slot blot techniques demonstrated that CEO pretreatment at concentrations of 2.5, 5, and 10 μg/mL significantly reduced 6-OHDA-induced oxidative DNA damage and restored the gene and protein expression of key antioxidant enzymes (GPx1, GPx4, SOD1, and CAT). These results highlight the powerful antioxidant and neuroprotective properties of CEO, supporting its potential as a therapeutic agent for neurodegenerative disorders related to oxidative stress, such as Parkinson's disease.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"4243787"},"PeriodicalIF":2.2,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EMPOWER-PD: Evaluation of an 8-Week Co-Designed Self-Management Program in People With Parkinson's Disease and Their Caregivers: An Intervention Study With Long-Term Follow-Up.","authors":"Trine Hørmann Thomsen, Sara Lungby Skovbølling, Maria Brønden, Jakob Frederiksen, Maja Hedegaard Lauritzen, Marcus Dalsgaard, Bo Biering-Sørensen","doi":"10.1155/padi/9413261","DOIUrl":"10.1155/padi/9413261","url":null,"abstract":"<p><p>Empowerment and implementation of self-management strategies are vital components in the future care of chronic, neurological patient groups, including people with Parkinson's disease (PD). This study aimed to evaluate the feasibility and effectiveness of an 8-week self-management intervention designed for people with PD (PwP) with follow-up assessments at 3 and 6 months postintervention. The program focused on developing self-management skills, coping strategies, disease education, mindfulness, exercise routines, and individual goal-setting tools. Objective measurements using Parkinson's KinetiGraph™ (PKG) were employed to monitor motor symptoms, immobility levels, and burden of nonmotor symptoms (self-reported in the PKG portal). Participants, serving as their own controls, were recruited from movement disorder clinics, private neurologists, and a specialized rehabilitation center. Primary endpoints were change in Health Education Impact Questionnaire (HeiQ) and Health Literacy Questionnaire (HLQ-14) scores, assessed at baseline and at 3- and 6-month follow-up. Secondary endpoints included changes in quality of life, self-efficacy, motor symptoms (PKG data), nonmotor symptoms, contacts to the clinics 6 months before and after the intervention, and time spent with immobility. Eighty PwP completed the program, and 59 caregivers attended the educational sessions. Statistically significant changes were found between baseline and follow-up in the motor symptom burden, self-efficacy, and reduced clinical contacts. Although no statistical changes were observed in health literacy, quality of life, and nonmotor symptoms, sustained positive trends were observed. The findings suggest that the program may enhance empowerment and self-management strategies in PwP, particularly in self-efficacy level, managing motor symptoms, and less need of contact to the clinics.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"9413261"},"PeriodicalIF":2.2,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes of Rotigotine in Parkinson's Disease: Real-World Evidence on Symptom Control and Quality of Life From China.","authors":"Xiaodong Zhu, Hongcan Zhu, Lei Chen, Tanja Heidbrede, Saori Shimizu, Yingyan Zhou, Weiwei Sun, Wenhuan Cheng, Guiyun Cui, Jian Wang","doi":"10.1155/padi/8839543","DOIUrl":"10.1155/padi/8839543","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is a progressive neurodegenerative disorder impacting the quality of life, with a notable prevalence worldwide, including China. Rotigotine, a silicone-based patch that transdermally delivers a dopamine agonist, has shown promise as a PD treatment option.</p><p><strong>Objective: </strong>This study aimed to evaluate the safety and effectiveness of rotigotine in a real-world Chinese population.</p><p><strong>Method: </strong>This multicenter, prospective, noninterventional postmarketing surveillance study was conducted across 27 hospitals in China from March 2021 to June 2023. It included adult patients with early and advanced idiopathic PD, newly initiating rotigotine (includes receiving rotigotine up to four weeks prior to enrollment). Safety was assessed through treatment-emergent adverse drug reactions (ADRs), serious adverse events (AEs) (SAEs), and treatment discontinuations due to AEs. Effectiveness was evaluated using the Patient Global Impression of Change (PGIC), Wearing-Off Questionnaire-9 (WOQ-9), and PD Questionnaire-8 (PDQ-8).</p><p><strong>Results: </strong>Of 829 enrolled patients, 803 were included in the safety set and 572 in the full analysis set. The study reported a safety profile consistent with previous studies, with the most common AE being application site pruritus. The incidence of ADRs was 17.6%, lower than in previous Chinese Phase 3 studies and a Japanese noninterventional study. Over half of the patients reported improvement in PD symptoms as per PGIC, and PDQ-8 scores indicated an overall improvement in quality of life, particularly in patients with advanced PD.</p><p><strong>Conclusions: </strong>This study reaffirms the safety and effectiveness of rotigotine in a real-world Chinese PD population, including both early and advanced stages, aligning with previous research findings.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"8839543"},"PeriodicalIF":2.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12672075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occurrence of Motor Complications and Gait Problems After Introduction of Medical Treatment in Parkinson's Disease.","authors":"Yasushi Osaki, Yukari Morita, Sho Ohtsuru, Tomohiro Shogase, Daiji Yoshimoto, Toshimasa Miyoshi, Tatsuya Ikeda, Yu Hashimoto, Takuya Matsushita","doi":"10.1155/padi/8857969","DOIUrl":"10.1155/padi/8857969","url":null,"abstract":"<p><strong>Background: </strong>Although patients with Parkinson's disease eventually experience motor complications and gait problems including falls, introducing the necessity for gait assistance, or freezing of gait, there may be a medication dose at which patients do not experience both in the early stage of the disease.</p><p><strong>Objectives: </strong>To identify the medication dose at which Parkinson's disease patients, diagnosed and treated at our hospital, did not experience motor complications and gait problems.</p><p><strong>Methods: </strong>We retrospectively reviewed the clinical course, including motor complications and gait problems, of 119 newly diagnosed patients with Parkinson's disease for 24 months after the introduction of medical treatment. According to the presence of motor complications and/or gait problems, we categorized the patients into Groups 1-3. We estimated the median latency of motor complications or gait problems by Kaplan-Meier survival analysis. We calculated the levodopa equivalent dose.</p><p><strong>Results: </strong>Group 1 contained 25 patients with neither motor complications nor gait problems; Group 2 contained 40 patients who experienced motor complications first with a median latency of 11 months; and Group 3 contained 54 patients who experienced gait problems first with a median latency of 9 months. There were significant differences in the levodopa equivalent dose at 24 months among the groups: 250 mg in Group 1, 300 mg in Group 2, and 225 mg in Group 3.</p><p><strong>Conclusions: </strong>Patients with Parkinson's disease receiving a levodopa equivalent dose between 225 and 300 mg did not experience motor complications and gait problems for 24 months after the introduction of medical treatment.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"8857969"},"PeriodicalIF":2.2,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145541769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower LEDD and Polypharmacy Rates Beyond the Honeymoon Period in Patients With Parkinson's Disease Integrative Western-Korean Medicine Interventions: A CARE-Compliant Case Series.","authors":"Cheol-Hyun Kim, Taeseok Ahn, Youngjo So, Hyeon-Gyu Cho, Jiwoo Kim, Jihyun Moon, Myungjin Oh, Sunny Kang, Sangho Ji, Linae Kim, Sangkwan Lee, Namkwen Kim","doi":"10.1155/padi/9860808","DOIUrl":"10.1155/padi/9860808","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is the second most common neurodegenerative disorder with significant social costs, mainly owing to hospitalization, which is frequently associated with high levodopa equivalent daily dose (LEDD) and polypharmacy rather than neurological symptoms alone. Integrative treatment combining Western and Korean medicine may help control these factors and reduce the need for hospitalization. We investigated the potential impact of integrative treatment on LEDD and polypharmacy in patients with PD > 5 years postdiagnosis.</p><p><strong>Methods: </strong>Fifteen patients with PD (KCD code G20), diagnosed > 5 years earlier, who received integrative treatment at Gwangju Korean Medicine Hospital, Wonkwang University, from April 1, 2022, to July 30, 2024, were enrolled. A retrospective chart review was conducted to collect demographic and clinical data, including LEDD, medication count, and treatment details. Summary statistics were presented as median (IQR) and mean ± SD.</p><p><strong>Results: </strong>In the integrative treatment cohort, the prevalence of both LEDD and polypharmacy was lower than that in studies involving conventional treatment alone. The mean LEDD was 321.71 (median, 200.0) mg, while only two patients exceeded the LEDD threshold of 300 mg, which was associated with motor complications. Polypharmacy was observed in 13.3% of patients and hyperpolypharmacy in 6.7%, representing lower proportions compared with previous reports on conventional treatments. Representative cases highlighted symptom improvement and a reduced need for medication with integrative approaches, particularly acupuncture and herbal medicine.</p><p><strong>Conclusion: </strong>These findings suggest that integrative treatment may contribute to lowering LEDD and medication counts in patients with PD, which could potentially reduce hospitalization rates and the associated social costs. Further prospective studies comparing the integrative and nonintegrative treatment groups are needed to clarify these findings and evaluate the role of integrative treatment in the long-term management of PD.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"9860808"},"PeriodicalIF":2.2,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12585846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Traumatic Injury in Patients With Early-Onset Parkinson's Disease: A Population-Based Matched Cohort Study.","authors":"Takenori Akaike, Toshiki Fukasawa, Etsuro Nakanishi, Soichiro Masuda, Satomi Yoshida, Ryosuke Takahashi, Koji Kawakami","doi":"10.1155/padi/6970763","DOIUrl":"10.1155/padi/6970763","url":null,"abstract":"<p><strong>Introduction: </strong>Early-onset Parkinson's disease (EOPD) shares similar clinical features to the late-onset form, but the risk of injury remains unclear. This study aimed to evaluate the risk of traumatic injury, including fracture, in patients with EOPD.</p><p><strong>Methods: </strong>This matched cohort study used a Japanese administrative claims database to compare the risk of traumatic injury and fracture between EOPD patients and the general population. EOPD was defined by diagnosis between ages 21 and 49 together with the initiation of anti-PD medication. Crude incidence rates and adjusted hazard ratios (aHRs) were estimated using Poisson and Cox regression models. Subgroup analyses were performed by age and sex.</p><p><strong>Results: </strong>In 368 EOPD patients and 1586 matched individuals from the general population, the traumatic injury rate was slightly higher in EOPD patients (9.5 vs. 7.9 events per 100 person-years), but the difference was not substantial (aHR, 1.2; 95% confidence interval [CI], 0.9-1.5). Fracture risk in the groups was similar, at 1.4 events per 100 person-years (aHR, 0.9; 95% CI, 0.5-1.6). Subgroup analyses showed an increased traumatic injury risk in EOPD patients aged 40-49 years (aHR, 1.4; 95% CI, 1.0-1.8) and in females (aHR, 1.3; 95% CI, 1.0-1.8). No clear differences were observed in other comparisons.</p><p><strong>Conclusion: </strong>No major difference in traumatic injury or fracture risk was found between EOPD patients and the general population. However, preventive interventions may be warranted for patients aged 40-49 years and for females due to their elevated injury risk.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"6970763"},"PeriodicalIF":2.2,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12535810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145337410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daily Fluid Intake in People With Newly Diagnosed Parkinson's Disease Is Reduced Compared With Controls.","authors":"Isobel J Sleeman, Angus D MacLeod, Clare Tarr, Collette McGhee, Claire Fyfe, Carrie Stewart, Karen Scott, Phyo Kyaw Myint, Alexandra M Johnstone","doi":"10.1155/padi/2440967","DOIUrl":"10.1155/padi/2440967","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is an age-related neurodegenerative condition with a range of motor and nonmotor symptoms. Nonmotor symptoms such as constipation and orthostatic hypotension can occur at any stage, while dysphagia is common in later stages of the disease. Previous work by our group showed that people with PD who lose weight within a year of diagnosis had a poorer prognosis. In this study, we explored whether fluid intake was also reduced in people with newly diagnosed PD.</p><p><strong>Materials and methods: </strong>We invited people with newly diagnosed PD (within 6 months of a diagnosis or longer if not requiring treatment) to join the study. Controls were household members of the participants with PD. Participants all underwent the same assessments, including a 24-h dietary recall, a video-recorded swallowing assessment, and grading of stool sample consistency using the Bristol Stool Chart.</p><p><strong>Results: </strong>We recruited 30 participants, 19 with PD and 11 household controls. People living with PD reported significantly lower fluid intake from drinks (control median = 1799 mL, PD median = 1124 mL, <i>p</i>=0.005 for difference in medians). People with PD drank fluid slightly slower than the controls, 6.0 mL/second vs 7.5 mL/second, but this did not reach statistical significance. Participants with PD had significantly harder stools than controls, with a mean Bristol Stool Chart number of 3.2 vs 4.6 for controls (<i>p</i>=0.01).</p><p><strong>Conclusion: </strong>PD is associated with significantly reduced intake of fluids from beverages around the time of diagnosis, which may contribute to constipation and orthostatic hypotension.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"2440967"},"PeriodicalIF":2.2,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12530918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining Medication Adherence in Patients Treated for Parkinson's Disease and Related Factors.","authors":"Mahboobeh Besharatpour, Amir Kavousi, Mehri Salari, Koorosh Etemad","doi":"10.1155/padi/8889957","DOIUrl":"10.1155/padi/8889957","url":null,"abstract":"<p><p>Parkinson's disease (PD) is the second most common neurological disease. This study explores the determinant factors influencing medication adherence and disease stage among PD patients. This study was conducted on 161 PD patients at the Neurology Clinic. The eight-item Morisky Medication Adherence Scale (MMAS-8) and the International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) were used. Medication adherence and disease stage were analyzed using the chi-square test to measure the association of qualitative variables, and the Kruskal-Wallis test to test the association of quantitative data. Ordinal logistic regression was used to relate study variables with study outcomes. Medication adherence has a significant association with PD duration, number of times of taking PD drugs daily, comorbidity, total number of medications used, side effects, and history of medication discontinuation. The mean score of MDS-UPDRS subscales significantly differs. Medication adherence levels are suboptimal among PD patients, with significant correlations between medication adherence and disease stage, motor symptoms, and motor side effect. These insights underscore the critical need for targeted interventions to improve medication adherence and mitigate disease burden in PD patients.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"8889957"},"PeriodicalIF":2.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Visual Evoked Potential and Optical Coherence Tomography in Parkinson's Disease: A Systematic Review and Meta-Analysis.","authors":"Zahra Hemmatian, Javad Heravian Shandiz, Ali Shoeibi, Nasser Shoeibi, Reyhane Shariati, Batool Haghighi, Firozeh Fereydouni, Negareh Yazdani","doi":"10.1155/padi/2386302","DOIUrl":"10.1155/padi/2386302","url":null,"abstract":"<p><p><b>Background:</b> Previous studies revealed that optical coherence tomography (OCT) and visual evoked potential (VEP) were impaired in patients with Parkinson's disease (PD), but the results were inconsistent; in this meta-analysis, we tried to answer this issue by including studies that performed these two tests on the same sample size. <b>Methods:</b> PubMed, Scopus, Cochrane, and Google Scholar were comprehensively reviewed to retrieve the published studies investigating changes in OCT and VEP responses in PD patients. We analyzed the pooled weighted difference in means between PD patients and healthy controls using the random-effects model. <b>Results:</b> Ten studies were included (12 sets of data), enrolling 337 PD patients and 273 healthy controls. The P100 latency in PD patients was significantly higher compared to healthy controls (difference in means = 6.16, 95% CI: 1.16-11.15, <i>p</i>=0.02, <i>n</i> = 11). Significant thinning of the retinal nerve fiber layer (difference in means = -4.38, 95% CI: -6.29 to -2.47, <i>p</i> ≤ 0.001, <i>n</i> = 11) was observed in the PD eyes compared to the healthy subjects. However, no statistically significant difference was found in the means of P100 amplitude (<i>p</i>=0.06) and the average central foveal thickness (<i>p</i>=0.08) between PD patients and the control group. There was a significant negative correlation between RNFL weighted mean difference and P100 latency (<i>r</i> = -0.65, <i>p</i> ≤ 0.001) in all subjects. <b>Conclusions:</b> Our results confirmed that Parkinson's patients showed significant thinning of RNFL thickness and prolonged P100 latency time.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2025 ","pages":"2386302"},"PeriodicalIF":2.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145207138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}